Baxter International (NYSE: BAX) shares fell nearly 15% after its Q3 earnings report revealed mixed results and weak guidance. While net sales increased 5% year-over-year to $2.84 billion, missing analyst estimates, adjusted net income declined 14% to $0.69 per share, though it surpassed projections. The significant market reaction was primarily driven by the company's disappointing full-year outlook, which forecast sales growth of only 1-2% and adjusted EPS of $2.35-$2.40, both below consensus expectations, signaling continued headwinds for the medical device firm.
Baxter International (BAX) reported mixed third-quarter results, triggering a nearly 15% share price decline. While net sales increased 5% year-over-year to $2.84 billion, this figure still fell short of the $2.88 billion consensus estimate. Adjusted net income, however, declined 14% to $0.69 per share but surprisingly surpassed analyst projections of $0.60. The profitability decline, despite revenue growth, highlights margin pressures. Segment performance was varied, with Pharmaceuticals leading with 7% growth to $632 million, and Healthcare Systems and Technologies growing 3% to $773 million. Conversely, the largest segment, Medical Products and Therapies, experienced a 1% decline, contributing to the overall mixed operational picture. The primary catalyst for the significant market reaction was the disappointing full-year guidance. Management now anticipates sales growth of only 1% to 2% and adjusted net income of $2.35 to $2.40 per share, both below average analyst estimates of $2.44. This subdued outlook signals ongoing challenges and a potential deceleration in growth for the medical device specialist.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.75
Ticker Sentiment
